Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A., a wholly-owned subsidiary of the company (Glenmark), today announced the launch of RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older. The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA) earlier this year. The company has attached media release in this regard.
The above information is a part of company’s filings submitted to BSE.
